ERBB2 (A775_G776insYVMA)

ERBB2 · Variant type: indel · HGVS: p.A775_G776insYVMA

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Mobocertinib	100.0%	0.0%	97.22
2	Canertinib	99.3%	0.7%	96.49
3	Pralsetinib	98.6%	1.4%	93.43
4	Lazertinib	98.5%	1.5%	97.47
5	Darovasertib	91.7%	8.3%	96.99
6	Vandetanib	85.2%	14.8%	95.74
7	Neratinib	82.4%	17.6%	93.18
8	Erlotinib	71.7%	28.3%	99.75
9	Avapritinib	62.0%	38.0%	97.73
10	Alpelisib	53.0%	47.0%	97.22
11	Pacritinib	33.9%	66.1%	88.64
12	Zanubrutinib	30.3%	69.7%	98.24
13	Defactinib	23.1%	76.9%	92.68
14	Mitapivat	23.0%	77.0%	100.00
15	Pirtobrutinib	17.1%	82.9%	99.49
16	Cobimetinib	15.8%	84.2%	100.00
17	Acalabrutinib	13.9%	86.1%	99.50
18	Gilteritinib	13.2%	86.8%	88.97
19	Sunitinib	13.1%	86.9%	91.73
20	Palbociclib	12.3%	87.8%	98.75
21	Quizartinib	11.4%	88.6%	99.50
22	Pexidartinib	10.7%	89.3%	99.49
23	Tivozanib	10.4%	89.6%	92.42
24	Selumetinib	9.9%	90.1%	100.00
25	Pemigatinib	9.8%	90.2%	98.23

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Mobocertinib	100.0%	—	—
Canertinib	99.3%	—	—
Pralsetinib	98.6%	—	—
Lazertinib	98.5%	—	—
Darovasertib	91.7%	—	—
Vandetanib	85.2%	—	—
Neratinib	82.4%	—	—
Erlotinib	71.7%	—	—
Avapritinib	62.0%	—	—
Alpelisib	53.0%	—	—
Pacritinib	33.9%	—	—
Zanubrutinib	30.3%	—	—
Defactinib	23.1%	—	—
Mitapivat	23.0%	—	—
Pirtobrutinib	17.1%	—	—
Cobimetinib	15.8%	—	—
Acalabrutinib	13.9%	—	—
Gilteritinib	13.2%	—	—
Sunitinib	13.1%	—	—
Palbociclib	12.3%	—	—
Quizartinib	11.4%	—	—
Pexidartinib	10.7%	—	—
Tivozanib	10.4%	—	—
Selumetinib	9.9%	—	—
Pemigatinib	9.8%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 16.0ms